Holen Sie sich die Stockscreener-App
0.3365
11.26%
-0.0427
Handel nachbörslich:
.34
0.0035
+1.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$0.3792
Offen:
$0.382
24-Stunden-Volumen:
2.94M
Relative Volume:
1.51
Marktkapitalisierung:
$83.77M
Einnahmen:
$9.10M
Nettoeinkommen (Verlust:
$-82.47M
KGV:
-0.5802
EPS:
-0.58
Netto-Cashflow:
$-72.32M
1W Leistung:
-20.11%
1M Leistung:
-28.48%
6M Leistung:
-58.57%
1J Leistung:
-70.22%
1-Tages-Spanne:
$0.3355
$0.3967
1-Wochen-Bereich:
$0.3352
$0.43
52-Wochen-Spanne:
$0.3352
$1.16
Vaxart Inc Stock (VXRT) Company Profile
Firmenname
Vaxart Inc
Sektor
Branche
Telefon
(650) 550-3500
Adresse
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie VXRT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.3365 | 83.77M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-15 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-29 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | Eingeleitet | Jefferies | Buy |
| 2021-06-11 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
Alle ansehen
Vaxart Inc Aktie (VXRT) Neueste Nachrichten
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vaxart reports inducement grants under Nasdaq listing rule - TipRanks
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa
Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan
B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - Marketscreener.com
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE
Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE
Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener
RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals
Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com
Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire
Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India
Vaxart Inc. (VXRT) reports earnings - Quartz
Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener
Vaxart, Inc. SEC 10-K Report - TradingView
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire
Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan
FDA Mid-Month ID Food Recall Safety Updates - ContagionLive
Pipeline - Vaxart Inc.
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire
Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq
Vaxart's Crucial 2024 Financial Update: Management to Reveal Full-Year Performance - Stock Titan
Vaxart starts early-stage study for its pill-based vaccine for norovirus -March 11, 2025 at 08:57 am EDT - Marketscreener.com
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate - GlobeNewswire
First-Ever Norovirus Pill Vaccine Enters Clinical Trials: Vaxart's Game-Changing Approach - StockTitan
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Our Science - Vaxart Inc.
Vaxart's Oral Norovirus Vaccine: Key Study Findings and Future Plans - Contagionlive.com
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults - The Manila Times
Vaxart (VXRT) Projected to Post Quarterly Earnings on Thursday - Defense World
Vaxart reports promising norovirus vaccine trial results By Investing.com - Investing.com Canada
Vaxart reports promising norovirus vaccine trial results - Investing.com
Vaxart Announces Publication Demonstrating the - GlobeNewswire
Can Vaxart's Oral Norovirus Vaccine Overcome Age-Related Immune Challenges? New Data Says Yes - Stock Titan
Finanzdaten der Vaxart Inc-Aktie (VXRT)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):